Andrew McConaghie
Senior Writer
Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Andrew McConaghie
Sofinnova Raises €333m For European Biotech Fund
Biopharma Can Live With Boris’s Brexit Deal – But Will It Pass?
Lilly Calls Time On UK Neuroscience Research Center
The closure reflects the consolidation of neuroscience research in Cambridge, Mass, and Brexit is not to blame, says Lilly.
Roche: We’ve Abandoned Budgets And It’s Liberated Employees
Bill Anderson says Roche has scrapped budgets and improved productivity and re-energized teams. But is it too good to be true?
GSK Puts Faith In Next Gen Respiratory, Real World Studies
A pioneer in the field, can GSK’s investment in real world studies pay off?
Woodford Debacle Is A Test Of UK Biotech’s Resilience
As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.